Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
about
Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral AnticoagulantsSpecial considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillationAsian strategy for stroke prevention in atrial fibrillationInternational Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial DescriptivesRationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa)Use of dabigatran vs. warfarin with low-molecular-weight heparin bridging in catheter ablation for atrial fibrillation patients with a low CHADS2 scoreTemporal trends in stroke incidence in South Asian, Chinese and white patients: A population based analysisAntiplatelet Therapy Combinations and Thrombogenicity in Patients with Non-Valvular Atrial Fibrillation.New oral anticoagulants may be particularly useful for asian stroke patientsStroke and bleeding risk in atrial fibrillation.Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for StrokeThe Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society.Influence of the characteristics of Japanese patients on the long-term outcomes after aortic valve replacement: results of a microsimulation.Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study.Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-AnalysisThe Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulantsPost-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillanceEfficacy And Safety of Dabigatran Etexilate Utilization With Concomitant Dual Antiplatelet Therapy In Atrial FibrillationThe Optimal Treatment For Atrial Fibrillation In Less Developed Countries.Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation.Challenges from Variation across Regions in Cost Effectiveness Analysis in Multi-Regional Clinical Trials.Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation.Secondary prophylactic treatment and long-term prognosis after TIA and different subtypes of stroke. A 25-year follow-up hospital-based observational study.Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience.Oral anticoagulants for Asian patients with atrial fibrillation.Potential use of NOACs in developing countries: pros and cons.Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials.Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation.2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.A 'reluctant' critical review: 'Manual for evidence-based clinical practice (2015)'.Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore.Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.Secondary prevention treatment after acute stroke in older South Asian, Chinese and other Canadians: a retrospective data analysis.Anticoagulation increases alveolar hemorrhage in mice infected with influenza A.Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project.Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
P2860
Q26750467-CB90486D-8854-4AF1-A52C-29E1A6CD7F53Q28072542-1E3632DB-C33E-431F-A071-83ED1E681160Q28072723-9B16E709-D24B-4737-863E-29C1C6CD4CF1Q28584460-EA26E69C-CD3A-45E0-8BB5-1283CE7B2F82Q33552973-8CA788FD-80E2-438D-9F42-DD519D90960CQ33685880-19BF9A81-52A2-45EE-9C1D-89195381C48BQ33703494-DFF96B40-D50C-4CBC-9914-865E4AF09499Q33740815-CE4AB33B-717B-4806-87AB-47B6B742960EQ33765879-65400471-CB3C-45F1-9F8F-F01689C04043Q34269633-EE15FABF-1B0A-46F2-9856-04FA5433FEBEQ34670524-6FC40B05-73A7-4C1F-9675-C2A4D36AF76DQ35028638-FB5D1B85-4EF0-41A6-9A0B-6ABD08440B5BQ35547679-EED7B438-09E2-4D49-A9CC-862023C4C92DQ35553343-C9FD0733-6657-46BC-AB51-C56416565523Q35974298-13378178-C70B-46E3-99ED-947CD44DC48CQ36396649-549B4F8C-F3D0-4C22-B254-79478E3FB040Q36773627-8BC6F1DC-865E-4A1C-BA39-B78FFA267E86Q37115151-37026551-9964-4777-B4BE-8B02C1970FE5Q37115550-F43D3A54-C89A-4338-B440-D1B5876CB81BQ37135634-AE58F9C4-274B-40A4-8577-64BB62974467Q37201505-B4383C33-B080-450D-89B3-1E8C6CD2D176Q37373007-75D5BCFF-E546-420F-B402-D73B00DFD0BFQ37382897-45F1069E-80B4-4645-8AB9-1FF071CBEDA0Q37599670-AF9F8F19-10ED-449B-AA1F-CBBC8B978FE3Q37634440-B6F337FF-3624-4E2B-9D37-5B692B27BE89Q38194842-3FEF1BB0-B970-47D8-8BBC-1ACEEFE3A5B9Q38210994-94313488-DCD3-4E88-8C23-0D137663D3CFQ38264260-5A2589D5-4A50-40A1-B473-B40B7C9A4EE9Q38372780-71406293-73AA-4F85-8030-454C0B159235Q38647787-29E8F1C6-CD49-4706-8AD0-16A2B659AB95Q38685671-F8FC0828-5F26-4F8E-B594-0FF294342F25Q39023182-25774AA9-F123-438F-9C39-EBA2B672B6C4Q39129273-86E8A8FB-2CB7-47B8-A42B-0DF7A872456AQ39217774-5BBDD011-D72F-4E5C-8EDA-423D63B424F4Q39556840-3CEC2EA1-5762-4C1D-AB9B-0CBBF23AF359Q39823839-370FB024-247C-4C45-95B8-010E466AA230Q40044766-91D7A7BD-FE3C-444F-AE2C-52BE4B8408DFQ40399798-F76701CC-0CF3-4F32-A8FD-5D032F857050Q40454302-A7FEA3C5-7AF2-4382-8258-1E46F0273947Q40731226-4EB7EFC4-B44B-49D8-A381-524A3CB67BF1
P2860
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Dabigatran versus warfarin: ef ...... ians with atrial fibrillation.
@en
type
label
Dabigatran versus warfarin: ef ...... ians with atrial fibrillation.
@en
prefLabel
Dabigatran versus warfarin: ef ...... ians with atrial fibrillation.
@en
P2093
P1433
P1476
Dabigatran versus warfarin: ef ...... ians with atrial fibrillation.
@en
P2093
Antonio L Dans
Chu-Pak Lau
Denis Xavier
Jyh-Hong Chen
Li Sheng Liu
Masahide Koyanagi
Masatsugu Hori
Michael D Ezekowitz
Mitsunori Watanabe
P304
P356
10.1161/STROKEAHA.113.000990
P407
P577
2013-06-06T00:00:00Z